FdaApplication
BLA 125545
Identifiers
- fda_app_no: BLA125545
Properties
| Property | Value |
|---|---|
| applicant_name | Hospira Inc., a Pfizer Company |
| application_type | BLA |
| approval_date | 2018-05-15 |
Revenue by product
RETACRIT
| Period | Revenue |
|---|---|
| Q4 2023 | $78.0M |
| Q3 2023 | $82.0M |
| Q2 2023 | $87.0M |
| Q1 2023 | $93.0M |
| Q4 2022 | $86.0M |
| Q3 2022 | $87.0M |
| Q2 2022 | $106.0M |
| Q1 2022 | $115.0M |
| Q4 2021 | $122.0M |
| Q3 2021 | $110.0M |
| Q2 2021 | $103.0M |
| Q1 2021 | $109.0M |
| Q4 2020 | $108.0M |
| Q3 2020 | $102.0M |
| Q2 2020 | $87.0M |
| Q1 2020 | $89.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
RETACRIT
| Period | Revenue |
|---|---|
| Q4 2023 | $78.0M |
| Q3 2023 | $82.0M |
| Q2 2023 | $87.0M |
| Q1 2023 | $93.0M |
| Q4 2022 | $86.0M |
| Q3 2022 | $87.0M |
| Q2 2022 | $106.0M |
| Q1 2022 | $115.0M |
| Q4 2021 | $122.0M |
| Q3 2021 | $110.0M |
| Q2 2021 | $103.0M |
| Q1 2021 | $109.0M |
| Q4 2020 | $108.0M |
| Q3 2020 | $102.0M |
| Q2 2020 | $87.0M |
| Q1 2020 | $89.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (7)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| RETACRIT | EPOETIN ALFA-EPBX | 2,000UNITS/ML | Injection |
| RETACRIT | EPOETIN ALFA-EPBX | 4,000UNITS/ML | Injection |
| RETACRIT | EPOETIN ALFA-EPBX | 10,000UNITS/ML | Injection |
| RETACRIT | EPOETIN ALFA-EPBX | 40,000UNITS/ML | Injection |
| RETACRIT | EPOETIN ALFA-EPBX | 3,000UNITS/ML | Injection |
| RETACRIT | — | 20,000UNITS/ML | Injection |
| RETACRIT | — | 20,000UNITS/2ML (10,000UNITS/ML) | Injection |
7 products